Skip to main content
Register for FutureLink Barcelona 2026 Today→
TraceLink — Network for Greater Good
AI Mode Agents AI Solutions Network Resources About
LOG IN TraceLink Classic OPUS Platform
Newsroom

Breadcrumb

  1. Home
  2. About
  3. Newsroom

TraceLink Achieves 69% Overall Revenue Growth in Q1 2018, Including 270% Revenue Growth in EMEA

  • Download PDF
  • Share
    • LinkedIn
    • Facebook
    • Mail
    • Twitter

Table of contents

TraceLink Inc., the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, today announced financial and company results for the first quarter of 2018.

Financial growth highlights for Q1 2018 include:

  • A 69 percent year-over-year increase in Q1 revenue, including revenue growth in the following regions:
    • 386 percent revenue growth in APAC
    • 270 percent revenue growth in EMEA; and,
    • 159 percent revenue growth in India.

  • A 43 percent year-over-year increase in all bookings for Q1, including a 177 percent increase in EMEA bookings for the quarter;

  • A two-year revenue compound annual growth rate (CAGR) of 70 percent; and,

  • A 38 percent annual increase in customers for a total of 821 customers across 35 countries, demonstrating the largest customer base for pharmaceutical track and trace and serialization, spanning all segments within the global life sciences supply chain, including:
    • 54 percent representing pharmaceutical and contract manufacturers;
    • 6 percent representing wholesale distributors and parallel importers; and
    • 40 percent representing pharmacies, hospitals and health systems.

“I am extremely pleased with our Q1 performance.  The investments we’ve made to grow our global business and serve customers in EMEA, APAC and the U.S. are paying off, enabling TraceLink to further advance its market share position as the only digital supply chain network for global serialization and track and trace,” said Shabbir Dahod, president and CEO, TraceLink. “As transaction activity on our network grows through the increasing number of TraceLink customers that are serializing products and exchanging data with their ecosystems of trade partners, we are setting the stage for future business transformation with applications that will deliver a new paradigm of real-time digital information sharing across the entire supply chain.”

Additional Q1 2018 growth highlights and milestones include:

  • Leading the market with the industry’s most serialization-ready companies - with over 390 companies live or configured to go live with TraceLink solutions, as of the end of Q1.

  • Demonstrating unmatched scalability by commissioning 43 million serial numbers in March, the highest month in Q1 for commissioned serial numbers – and a 106 percent increase in serial numbers commissioned year-over-year, for a total of 670 million serial numbers commissioned to date.

  • Accelerating company and trade partner connectivity as a result of the “network effect” on the Life Sciences Cloud with:
    • More than 200 contract manufacturing organizations (CMOs) fully configured on the TraceLink Life Sciences Cloud and ready to exchange serialization data;
    • An additional 450 CMOs currently in active testing on the TraceLink network and projected to be serialization ready in a matter of months; and,
    • More than 4,600 links, or individual connections for serialization, between a customer and a trade partner, on the Life Sciences Cloud.

  • Processing global compliance reports for millions of product units – processing over 62,000 compliance documents for more than 186 million units of product in the EU, China, Brazil, India and South Korea.

  • Demonstrating the success of our easy-to-use system – with a total of 45,000 users regularly accessing the Life Sciences Cloud.

  • Unveiling EU FMD Express, a purpose-built compliance solution for smaller pharmaceutical companies – providing a cost-effective, simplified solution designed specifically to address the needs of smaller pharmaceutical companies complying with the EU Falsified Medicines Directive (FMD.)

  • Publishing the full analysis from the Global Drug Supply, Safety and Traceability Report, the industry’s largest survey on life science companies’ readiness for serialization deadlines - including data from 660 respondents in the pharmaceutical supply chain, and revealing a major disparity in industry’s readiness to comply with track and trace regulations in the U.S. and EU

  • Setting the stage for FutureLink Munich, by partnering with global visionaries and industry thought leaders to deliver over 20 speaking sessions – through two separate tracks focused on Global Serialization and Compliance and Digital Drug Supply, Networks and Value.

Table of contents

Cookie Settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies or similar tracking technologies. Please see below for an overview of the categories of cookies and similar technologies used on this site. You can allow or deny some of all of them, except Strictly Necessary Cookies which are required to provide the site to you. However, blocking some types of cookies may impact your experience of the site and services we are able to offer.

Please see our Cookie Policy for more details, including a list of the cookies we use. You can change your consent options at any time by following the “Cookie Settings” link in the Cookie Policy.
'Strictly Necessary' cookies let you move around the Site and use essential features like secure areas, shopping baskets and online billing. Without these cookies you would not be able to navigate between pages or use certain vital features of our Site, so we do not require your consent for their use. These cookies don't gather any information about you that could be used for marketing or remembering where you've been on the internet. For example, we use these Strictly Necessary cookies to identify you as being logged in to the Site. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the Site will not work.
'Performance' cookies collect information about how you use the Site, such as which pages you visit, the time spent on the Site and if you experience any errors. We use performance cookies to provide aggregated statistics on how the Site is used and help us improve the Site including by measuring any errors that occur.
'Functional' cookies are used to provide services or to remember settings to improve your visit. We use 'Functionality' cookies to remember your settings and choices and show you when you're logged in to the Site.
‘Targeting' cookies are linked to services provided by third parties, such as 'Like' buttons and 'Share' buttons. The third party provides these services in return for recognizing that you have visited the Site. We also use 'Targeting' cookies to gather information that could be used to display content that we think may interest you.
Register for FutureLink Barcelona 2026 Today→
TraceLink — Network for Greater Good
Log In OPUS Platform · TraceLink Classic
AI Mode
Featured Report The Agentic Supply Chain Operating Model →

Agentic Business Processes

External Manufacturing Logistics Transportation Commerce Compliance

Products

Digital Transaction Exchange Process Collaboration Global Track-and-Trace Regulatory Compliance Real-Time Intelligence

Resources

Resource Center TraceLink University Partners Community Customers Events

About TraceLink

Newsroom Culture & Careers Open Jobs Legal & Trust Center Corporate Social Responsibility Network Directory Glossary

Hot Topics

Eliminate Stockouts Improve OTIF Reduce Costs Increase End-to-End Visibility Accelerate Order-to-Cash Optimize Inventory Levels Scale Cross-Partner Execution
Need assistance? Contact Technical Support→

Contact Us Today

Transform your supply chain operations with a human-agent workforce.

Contact Us →

Stay Up-to-Date

Subscribe to receive industry insights and evolving trends.

Thanks — you're subscribed.

© TraceLink Inc. 2009–2026 All Rights Reserved